I am incredibly excited and humbled that the @US_FDA has approved trials of the drug my lab discovered (@pulmotect PUL-042) to fight #COVID19 #pneumonia in diagnosed patients (NCT04312997) and exposed #HealthcareWorkers and contacts (NCT04313023). 
This has taken herculean effort by the @pulmotect team to get through the regulatory steps and by the @MDAndersonNews team to prepare for implementation.
A special thanks to all Evans Lab members, past and present, members of the Dickey lab, and the MD Anderson Department of Pulmonary Medicine, as well as all of our colleagues, collaborators and supporters. I truly think this will benefit people, and you all contributed critically
I should note that preclinical work was supported by @NIH & @NIHDirector (DP2); @nih_nhlbi & @NHLBI_LUNGDir (R35, R01, DP2); @NIAIDFunding (U01); @theNCI (P30); @LLSusa ; @CPRITTexas ; @MDAndersonNews ; @tjmartell ; Cyrus Family Foundation
